Alligator Bioscience develops antibody-based pharmaceuticals for cancer treatment. The Company is specialized in the development of tumor-targeted immunotherapies, particularly agonistic mono- and bispecific antibodies, and is engaged in the early stages of drug development, from the idea stage to clinical phase II trials.

TypePublic
HQLund, SE
Founded2001
Size (employees)47 (est)+31%
Websitealligatorbioscience.se
Alligator Bioscience was founded in 2001 and is headquartered in Lund, SE
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Alligator Bioscience Office Locations

Alligator Bioscience has an office in Lund
Lund, SE (HQ)
2 Scheelevägen
Show all (1)
Report incorrect company information

Alligator Bioscience Online and Social Media Presence

Embed Graph
Report incorrect company information

Alligator Bioscience Blogs

Alligator Bioscience receives government research grant

Lund, Sweden, October 5, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announced that they will receive a 500 000 SEK grant from Sweden’s government agency for innovation, Vinnova, f…

VD Per Norlén kommenterar nobelpriset i fysiologi eller medicin 2018

Måndagen den 1 oktober stod det klart att James P. Allison och Tasuku Honjo tilldelas 2018 års nobelpris i fysiologi eller medicin för deras upptäckt av cancerbehandling genom hämning av immunförsvarets bromsmekanismer– en upptäckt som Nobelförsamlingen vid Karolinska Institutet bedömer ”har revolut…

CEO Per Norlén comments on the Nobel Prize in Physiology or Medicine 2018

On Monday October 1st the Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation – a discovery the Nobel Assembly at Karolinska Institutet said has “revolutionized cancer tr…

Nya prekliniska data stödjer goda säkerhetsegenskaper för 4-1BB-antikroppen ATOR-1017

Lund den 28 september 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), ett bioteknikbolag som utvecklar antikroppsbaserade läkemedelskandidater för tumörriktad immunterapi, kommer att presentera prekliniska data för läkemedelskandidaten ATOR-1017 vid den vetenskapliga konferensen 4th CRI-CIMT-…

New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017

Lund, Sweden, September 28, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present preclinical safety data for the drug candidate ATOR-1017 at the 4th CRI-CIMT-EATI-AACR International Can…

Alligator Bioscience presents at the 20th Annual Rodman & Renshaw Global Investment Conference

Lund, Sweden, August 30 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Con…
Show more

Alligator Bioscience Company Life and Culture

Report incorrect company information